In this presentation, data sourced from the CIBM-TR registry were utilized to assess the differential outcomes of Brexu-cel therapy in patients with R/R MCL exhibiting high-risk features, such as delTP53/17P, high Ki-67 (≥50%), and eligibility for ZUMA-2 clinical trials.
The data analysis encompassed 456 adult patients who underwent Brexu-cel therapy, with a median follow-up period of 12.3 months. Notably, 42% of these patients presented with delTP53/17P and/or high Ki-67 and 57% of the cohort would have been ineligible for ZUMA-2, due to the presence of comorbidities before infusion.
The examination of efficacy and safety revealed consistent ORR and CR rates across all treated high-risk subgroups. The median DOR had not yet been reached. No statistically significant differences were observed in OS and PFS at any designated time point. Following multivariate adjustment, Bruxa-cel exhibited comparable efficacy and safety profiles in patients both with and without high-risk features. While numerically longer OS and PFS were noted in patients without high-risk features, statistical significance was not demonstrated.
This real-world study lends support to the proposition that Bruxa-cel should be considered a standard of care in the treatment of R/R MCL patients, including those presenting with high-risk features.
Kambhampati S et al, Real-World Outcomes of Brexucabtagene Autoleucel (Brexu-cel) for Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL): A CIBMTR Subgroup Analysis of High-Risk Characteristics. 2023, #ASH107
With the educational support of: